Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 24 March 2022, 10:05 HKT/SGT
Share:
    

Source: Denso
Joint Research Shows that DENSO's Microalga, Coccomyxa sp. KJ Has Virucidal Effect against COVID-19

TOKYO, Mar 24, 2022 - (JCN Newswire) - Chubu University, Tokai University, Tohoku University School of Medicine and DENSO Corporation have found that monogalactosyl diacylglyceride (MGDG), a component contained in the chloroplasts of a microalga called Coccomyxa sp. KJ(1), has a virucidal effect(2) against COVID-19.


Coccomyxa sp. KJ is a fast-growing, vigorous, and easy-to-cultivate microalga. The plant contains not only abundant nutrients, including vitamins and amino acids, but also unique characteristics, such as suppressing an increase in the bacteria that cause periodontal disease. Moreover, in 2019, it was found that MGDG contained in Coccomyxa sp. KJ breaks the envelope membranes(3) of herpesviruses and has a virucidal effect against the viruses.

Recently, the three universities and DENSO discovered that MGDG contained in Coccomyxa sp. KJ also has a virucidal effect against COVID-19. The group will also research whether this microalga MGDG has a virucidal effect against influenza viruses, human coronaviruses, and other viruses with envelope membranes other than herpesviruses and COVID-19.

The results of the research may lead to the development of products that effectively counter COVID-19 and other viruses. The three universities and DENSO will continue to conduct this research to expand the scope of measures for preventing infectious diseases to contribute to society.

As an academia-industry collaboration project with the grant number JPMJTR204H, the research was conducted with support from the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) funded by the Japan Science and Technology Agency (JST).
Glossary

(1) Coccomyxa sp. KJ is a registered trademark of DENSO Corporation. This microalga was developed by DENSO jointly with Kyoto University. "Stories," one of the DENSO-owned media, also features the plant: bit.ly/3JDGt38
(2) Virucidal effect means destroying the ability of viruses to infect cells.
(3) Envelope membranes are found in virus particles.


Topic: Press release summary
Source: Denso

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Denso Links

http://www.globaldenso.com/en/

https://www.facebook.com/DENSOCorporation/

https://twitter.com/hashtag/denso?lang=en

https://www.youtube.com/channel/UCl8cZy9vYlTcnkVMEInM7XQ

https://ph.linkedin.com/company/denso

Denso
Oct 30, 2025 16:29 HKT/SGT
DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 21:53 HKT/SGT
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 10, 2025 23:21 HKT/SGT
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 10, 2025 23:08 HKT/SGT
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Sept 29, 2025 14:22 HKT/SGT
DENSO and TUV Rheinland Japan Sign Memorandum of Understanding to Realize Sustainable Product Development and to Promote Digital Product Passport
Sept 25, 2025 17:02 HKT/SGT
JERA and DENSO Begin Japan's First Demonstration of SOEC Hydrogen Production at a JERA Thermal Power Station
Sept 1, 2025 19:52 HKT/SGT
DENSO Signs Agreement to Transfer Part of Its Ceramic Product Business
Aug 28, 2025 15:33 HKT/SGT
The University of Tokyo and DENSO Jointly Establish a Social Cooperation Program: "Building Sustainable Production System Infrastructure with Advanced AI Technology"
Aug 6, 2025 17:54 HKT/SGT
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 1, 2025 10:00 HKT/SGT
Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: